uniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B

November 15, 2018 7:20 AM

uniQure (NASDAQ: QURE) Climbs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found